His­toric drug pric­ing re­forms pass; Pfiz­er ac­quires GBT; The long search for non-opi­oid pain drugs; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The End­points Week­ly has of­fi­cial­ly crossed the 60,000 mark on sub­scribers — thanks to all of your sup­port. As the ed­i­to­r­i­al team grows, we’ve been able to do a lot more, with many of those on dis­play this week. Be sure to check out Lei Lei Wu’s deep dive on pain R&D. If you missed it, you may al­so re­watch her com­pan­ion pan­el here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER